Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
65.13
+1.91 (+3.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Incyte Corp
< Previous
1
2
3
4
5
6
Next >
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 01, 2022
From
Incyte
Via
Business Wire
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
October 19, 2022
From
Incyte
Via
Business Wire
Incyte to Report Third Quarter Financial Results
October 11, 2022
From
Incyte
Via
Business Wire
Incyte Names New Member to Its Board of Directors
October 04, 2022
From
Incyte
Via
Business Wire
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
October 03, 2022
From
Incyte
Via
Business Wire
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
August 26, 2022
From
Incyte
Via
Business Wire
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
August 24, 2022
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
August 23, 2022
From
Incyte
Via
Business Wire
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 02, 2022
From
Incyte
Via
Business Wire
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
July 18, 2022
From
Incyte
Via
Business Wire
Incyte to Report Second Quarter Financial Results
July 12, 2022
From
Incyte
Via
Business Wire
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
May 26, 2022
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
May 24, 2022
From
Incyte
Via
Business Wire
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
May 05, 2022
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
May 04, 2022
From
Incyte
Via
Business Wire
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 03, 2022
From
Incyte
Via
Business Wire
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
April 28, 2022
From
Incyte
Via
Business Wire
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
April 22, 2022
From
Incyte
Via
Business Wire
Incyte to Report First Quarter Financial Results
April 12, 2022
From
Incyte
Via
Business Wire
Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
March 26, 2022
From
Incyte
Via
Business Wire
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
March 25, 2022
From
Incyte
Via
Business Wire
Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
March 18, 2022
From
Incyte
Via
Business Wire
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
March 14, 2022
From
Incyte Corporation
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
February 15, 2022
From
Incyte
Via
Business Wire
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
February 08, 2022
From
Incyte Corporation
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
February 03, 2022
From
Incyte
Via
Business Wire
Incyte Provides Update on Parsaclisib and MCLA-145
January 25, 2022
From
Incyte
Via
Business Wire
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
January 20, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s...
Via
FinancialNewsMedia
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
January 18, 2022
From
Incyte
Via
Business Wire
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
January 14, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.